Combination therapy for untreated advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with head and neck cancer that is locally advanced and cannot be completely removed by surgery.
- You have not had any prior treatment for this cancer (like chemo, radiation, or immunotherapy).
- You are generally in good health, able to care for yourself, and at least 18 years old.
- Your kidney, liver, and blood cell counts are within a certain healthy range.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new LA HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.